Bacteremia in critical care units at Bugando Medical Centre, Mwanza, Tanzania: the role of colonization and contaminated cots and mothers' hands in cross-transmission of multidrug resistant Gram-negative bacteria.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
06 05 2020
Historique:
received: 29 01 2020
accepted: 22 04 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 2 4 2021
Statut: epublish

Résumé

Multidrug resistance (MDR) is a major clinical problem in tertiary hospitals in Tanzania and jeopardizes the life of neonates in critical care units (CCUs). To better understand methods for prevention of MDR infections, this study aimed to determine, among other factors, the role of MDR-Gram-negative bacteria (GNB) contaminating neonatal cots and hands of mothers as possible role in transmission of bacteremia at Bugando Medical Centre (BMC), Mwanza, Tanzania. This cross-sectional, hospital-based study was conducted among neonates and their mothers in a neonatal intensive care unit and a neonatology unit at BMC from December 2018 to April 2019. Blood specimens (n = 200) were sub-cultured on 5% sheep blood agar (SBA) and MacConkey agar (MCA) plates. Other specimens (200 neonatal rectal swabs, 200 maternal hand swabs and 200 neonatal cot swabs) were directly inoculated on MCA plates supplemented with 2 μg/ml cefotaxime (MCA-C) for screening of GNB resistant to third generation cephalosporins, r-3GCs. Conventional biochemical tests, Kirby-Bauer technique and resistance to cefoxitin 30 μg were used for identification of bacteria, antibiotic susceptibility testing and detection of MDR-GNB and screening of potential Amp-C beta lactamase producing GNB, respectively. The prevalence of culture confirmed bacteremia was 34.5% of which 85.5% were GNB. Fifty-five (93.2%) of GNB isolated from neonatal blood specimens were r-3GCs. On the other hand; 43% of neonates were colonized with GNB r-3GCs, 32% of cots were contaminated with GNB r-3GCs and 18.5% of hands of neonates' mothers were contaminated with GNB r-3GCs. The prevalences of MDR-GNB isolated from blood culture and GNB r-3GCs isolated from neonatal colonization, cots and mothers' hands were 96.6, 100, 100 and 94.6%, respectively. Significantly, cyanosis (OR[95%CI]: 3.13[1.51-6.51], p = 0.002), jaundice (OR[95%CI]: 2.10[1.07-4.14], p = 0.031), number of invasive devices (OR[95%CI]: 2.52[1.08-5.85], p = 0.031) and contaminated cot (OR[95%CI]: 2.39[1.26-4.55], p = 0.008) were associated with bacteremia due to GNB. Use of tap water only (OR[95%CI]: 2.12[0.88-5.09], p = 0.040) was protective for bacteremia due to GNB. High prevalence of MDR-GNB bacteremia and intestinal colonization, and MDR-GNB contaminating cots and mothers' hands was observed. Improved cots decontamination strategies is crucial to limit the spread of MDR-GNB. Further, clinical presentations and water use should be considered in administration of empirical therapy whilst awaiting culture results.

Sections du résumé

BACKGROUND
Multidrug resistance (MDR) is a major clinical problem in tertiary hospitals in Tanzania and jeopardizes the life of neonates in critical care units (CCUs). To better understand methods for prevention of MDR infections, this study aimed to determine, among other factors, the role of MDR-Gram-negative bacteria (GNB) contaminating neonatal cots and hands of mothers as possible role in transmission of bacteremia at Bugando Medical Centre (BMC), Mwanza, Tanzania.
METHODS
This cross-sectional, hospital-based study was conducted among neonates and their mothers in a neonatal intensive care unit and a neonatology unit at BMC from December 2018 to April 2019. Blood specimens (n = 200) were sub-cultured on 5% sheep blood agar (SBA) and MacConkey agar (MCA) plates. Other specimens (200 neonatal rectal swabs, 200 maternal hand swabs and 200 neonatal cot swabs) were directly inoculated on MCA plates supplemented with 2 μg/ml cefotaxime (MCA-C) for screening of GNB resistant to third generation cephalosporins, r-3GCs. Conventional biochemical tests, Kirby-Bauer technique and resistance to cefoxitin 30 μg were used for identification of bacteria, antibiotic susceptibility testing and detection of MDR-GNB and screening of potential Amp-C beta lactamase producing GNB, respectively.
RESULTS
The prevalence of culture confirmed bacteremia was 34.5% of which 85.5% were GNB. Fifty-five (93.2%) of GNB isolated from neonatal blood specimens were r-3GCs. On the other hand; 43% of neonates were colonized with GNB r-3GCs, 32% of cots were contaminated with GNB r-3GCs and 18.5% of hands of neonates' mothers were contaminated with GNB r-3GCs. The prevalences of MDR-GNB isolated from blood culture and GNB r-3GCs isolated from neonatal colonization, cots and mothers' hands were 96.6, 100, 100 and 94.6%, respectively. Significantly, cyanosis (OR[95%CI]: 3.13[1.51-6.51], p = 0.002), jaundice (OR[95%CI]: 2.10[1.07-4.14], p = 0.031), number of invasive devices (OR[95%CI]: 2.52[1.08-5.85], p = 0.031) and contaminated cot (OR[95%CI]: 2.39[1.26-4.55], p = 0.008) were associated with bacteremia due to GNB. Use of tap water only (OR[95%CI]: 2.12[0.88-5.09], p = 0.040) was protective for bacteremia due to GNB.
CONCLUSION
High prevalence of MDR-GNB bacteremia and intestinal colonization, and MDR-GNB contaminating cots and mothers' hands was observed. Improved cots decontamination strategies is crucial to limit the spread of MDR-GNB. Further, clinical presentations and water use should be considered in administration of empirical therapy whilst awaiting culture results.

Identifiants

pubmed: 32375857
doi: 10.1186/s13756-020-00721-w
pii: 10.1186/s13756-020-00721-w
pmc: PMC7201549
doi:

Substances chimiques

Cefotaxime N2GI8B1GK7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

58

Subventions

Organisme : Medical Research Council
ID : MR/S004815/1
Pays : United Kingdom

Références

J Antimicrob Chemother. 2018 Jun 1;73(6):1460-1463
pubmed: 29481657
Front Microbiol. 2016 Dec 01;7:1862
pubmed: 27990135
J Pathog. 2016;2016:4065603
pubmed: 26942013
Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14
pubmed: 23221186
Int J Med Microbiol. 2018 Oct;308(7):803-811
pubmed: 29980372
J Clin Microbiol. 2011 Aug;49(8):2798-803
pubmed: 21632895
Crit Care. 2016 Jun 22;20(1):136
pubmed: 27329228
J Hosp Infect. 2012 Jan;80(1):56-60
pubmed: 21975219
Infection. 1999;27 Suppl 2:S19-23
pubmed: 10885822
Clin Infect Dis. 2009 Mar 1;48(5):580-6
pubmed: 19191643
Antimicrob Resist Infect Control. 2019 May 22;8:84
pubmed: 31143444
Hepatology. 2007 Jan;45(1):230-41
pubmed: 17187426
Rev Esp Quimioter. 2019 Aug;32(4):303-310
pubmed: 31257821
BMC Infect Dis. 2016 Oct 20;16(1):587
pubmed: 27765017
J Antimicrob Chemother. 2019 Oct 1;74(10):2880-2890
pubmed: 31361004
J Hosp Infect. 2019 May;102(1):98-100
pubmed: 30195721
Int J Antimicrob Agents. 2008 May;31(5):434-9
pubmed: 18328674
J Lab Physicians. 2014 Jan;6(1):1-6
pubmed: 24696552
BMC Res Notes. 2014 May 03;7:279
pubmed: 24886506
J Intensive Care. 2017 Mar 3;5:22
pubmed: 28270914
Am J Clin Pathol. 1966 Apr;45(4):493-6
pubmed: 5325707
Crit Care Med. 2012 Apr;40(4):1045-51
pubmed: 22202707
Clin Infect Dis. 2004 Oct 15;39(8):1182-9
pubmed: 15486843
PLoS One. 2013;8(1):e54703
pubmed: 23372757
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Open Forum Infect Dis. 2017 Feb 10;4(1):ofx014
pubmed: 28480285
Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents
pubmed: 19136439
BMC Pediatr. 2010 Jun 04;10:39
pubmed: 20525358
Zoonoses Public Health. 2015 Nov;62(7):557-68
pubmed: 25753615
FEMS Microbiol Ecol. 2016 May;92(5):fiw065
pubmed: 27020061
Saudi J Anaesth. 2018 Jul-Sep;12(3):389-394
pubmed: 30100836
Pediatr Infect Dis J. 1999 Oct;18(10 Suppl):S23-31
pubmed: 10530570
J Korean Med Sci. 2010 Jul;25(7):999-1004
pubmed: 20592889
BMC Infect Dis. 2016 Dec 13;16(1):756
pubmed: 27964724
J Clin Diagn Res. 2014 Apr;8(4):DC16-9
pubmed: 24959443
J Intensive Care. 2015 Dec 10;3:54
pubmed: 26693023

Auteurs

Vitus Silago (V)

Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, P. O. Box 1464, Bugando, Mwanza, Tanzania. vsilago.silago2@gmail.com.
Department of Veterinary Microbiology, Parasitology and Biotechnology, College of Veterinary Medicine and Biomedical Sciences, Sokoine University of Agriculture, P. O. Box 3000, Morogoro, Tanzania. vsilago.silago2@gmail.com.

Dory Kovacs (D)

Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.

Delfina R Msanga (DR)

Department of Pediatrics and Child Health, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, P. O. Box 1464, Bugando, Mwanza, Tanzania.

Jeremiah Seni (J)

Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, P. O. Box 1464, Bugando, Mwanza, Tanzania.

Louise Matthews (L)

Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.

Katarina Oravcová (K)

Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.

Ruth N Zadoks (RN)

Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.
Sydney School of Veterinary Science, University of Sydney, Sydney, Australia.

Athumani M Lupindu (AM)

Department of Veterinary Medicine and Public Health, College of Veterinary Medicine and Biomedical Sciences, Sokoine University of Agriculture, P. O. Box 3000, Morogoro, Tanzania.

Abubakar S Hoza (AS)

Department of Veterinary Microbiology, Parasitology and Biotechnology, College of Veterinary Medicine and Biomedical Sciences, Sokoine University of Agriculture, P. O. Box 3000, Morogoro, Tanzania.

Stephen E Mshana (SE)

Department of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, P. O. Box 1464, Bugando, Mwanza, Tanzania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH